First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases:A 2020 Delphi consensus  

作　　者：Maryam Alkhatry Ahmad Al-Rifai Vito Annese Filippos Georgopoulos Ahmad N Jazzar Ahmed M Khassouan Zaher Koutoubi Rahul Nathwani Mazen S Taha Jimmy K Limdi 

机构地区：[1]Gastroenterology and Endoscopy Department,Ibrahim Bin Hamad Obaid Allah Hospital,Ministry of Health and Prevention,Ras Al Khaiman,United Arab Emirates [2]Department of Gastroenterology,Sheikh Shakbout Medical City,Abu Dhabi,United Arab Emirates [3]Department of Gastroenterology,Valiant Clinic,Dubai,United Arab Emirates [4]Department of Gastroenterology and Endoscopy,American Hospital,Dubai,United Arab Emirates [5]Gastroenterology and Endoscopy Unit,Al Zahra Hospital,Dubai,United Arab Emirates [6]Gastroenterology Division,Sheikh Khalifa Medical City,Abu Dhabi,United Arab Emirates [7]Digestive Disease Unit,Rashid Hospital,Dubai,United Arab Emirates [8]Digestive Disease Institute,Cleveland Clinic,Abu Dhabi,United Arab Emirates [9]Department of Gastroenterology,Mediclinic City Hospital,Dubai,United Arab Emirates [10]Gastroenterology and Hepatology,Tawam Hospital,Al Ain,United Arab Emirates [11]Department of Gastroenterology,The Pennine Acute Hospitals NHS Trust,Manchester Academic Health Sciences,University of Manchester,Manchester M85RB,United Kingdom

出　　处：《World Journal of Gastroenterology》2020年第43期6710-6769,共60页世界胃肠病学杂志（英文版）

基　　金：Supported by Emirates Gastroenterology and Hepatology Society,No.001802.

摘　　要：Ulcerative colitis and Crohn’s disease are the main entities of inflammatory bowel disease characterized by chronic remittent inflammation of the gastrointestinal tract.The incidence and prevalence are on the rise worldwide,and the heterogeneity between patients and within individuals over time is striking.The progressive advance in our understanding of the etiopathogenesis coupled with an unprecedented increase in therapeutic options have changed the management towards evidence-based interventions by clinicians with patients.This guideline was stimulated and supported by the Emirates Gastroenterology and Hepatology Society following a systematic review and a Delphi consensus process that provided evidence-and expert opinion-based recommendations.Comprehensive up-to-date guidance is provided regarding diagnosis,evaluation of disease severity,appropriate and timely use of different investigations,choice of appropriate therapy for induction and remission phase according to disease severity,and management of main complications.

关 键 词：Ulcerative colitis Crohn’s disease INFLIXIMAB ADALIMUMAB Vedolizumab USTEKINUMAB Tofacitinib 

分 类 号：R574.6[医药卫生—消化系统]